Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$CIEN Ciena: The Risk/Reward Profile Is Attractive, Says William Blair http://www.smarteranalyst.com/2014/12/12/ciena-the-riskreward-profile-is-attractive-says-william-blair/
$CALL Canaccord Maintains Hold On Vocaltec Communications Following A Review Of 10-Q http://www.smarteranalyst.com/2014/12/12/canaccord-maintains-hold-on-vocaltec-communications-following-a-review-of-10-q/
$TEVA Deutsche Bank Maintains Buy On Teva Following Meeting With Management; Raises PT http://www.smarteranalyst.com/2014/12/12/deutsche-bank-maintains-buy-on-teva-following-meeting-with-management-raises-pt/
$CANF Can-Fite Represents An Undervalued Player With Significant Upside, Says H.C. Wainwright http://www.smarteranalyst.com/2014/12/12/can-fite-represents-an-undervalued-player-with-significant-upside-says-h-c-wainwright/
$CSIQ Canadian Solar's Shares Are Attractive At Current Levels, Says Roth Capital http://www.smarteranalyst.com/2014/12/12/canadian-solars-shares-are-attractive-at-current-levels-says-roth-capital/
$DVAX Cowen Maintains Outperform On Dynavax Following R&D Day http://www.smarteranalyst.com/2014/12/12/cowen-maintains-outperform-on-dynavax-following-rd-day/
$DVAX Cowen Maintains Outperform On Dynavax Following R&D Day http://www.smarteranalyst.com/2014/12/12/cowen-maintains-outperform-on-dynavax-following-rd-day/
$PPHM Roth Capital Maintains Buy On Peregrine Pharma Following F2Q15 Results http://www.smarteranalyst.com/2014/12/12/roth-capital-maintains-buy-on-peregrine-pharma-following-f2q15-results/
$LULU Lululemon: Improving Sales And Traffic Augur Well For 2015, Says Wedbush http://www.smarteranalyst.com/2014/12/11/lululemon-improving-sales-and-traffic-augur-well-for-2015-says-wedbush/
RadioShack Cost Cuts Way Too Late To Save Them, Says Wedbush http://www.smarteranalyst.com/2014/12/11/radioshack-cost-cuts-way-too-late-to-save-them-says-wedbush/
$WAG William Blair Reiterates Outperform On Walgreen Following CEO Transition http://www.smarteranalyst.com/2014/12/11/william-blair-reiterates-outperform-on-walgreen-following-ceo-transition/
$WAG William Blair Reiterates Outperform On Walgreen Following CEO Transition http://www.smarteranalyst.com/2014/12/11/william-blair-reiterates-outperform-on-walgreen-following-ceo-transition/
$LULU William Blair Maintains Market Perform On Lululemon Following Third Quarter Earnings http://www.smarteranalyst.com/2014/12/11/william-blair-maintains-market-perform-on-lululemon-following-third-quarter-earnings/
$TC Deutsche Bank Downgrades Thompson Creek Metals To Hold As Balance Sheet Continues To Strain http://www.smarteranalyst.com/2014/12/11/deutsche-bank-downgrades-thompson-creek-metals-to-hold-as-balance-sheet-continues-to-strain/
$ONCS H.C. Wainwright Maintains Buy On OncoSec Following FY1Q15 Update http://www.smarteranalyst.com/2014/12/11/h-c-wainwright-maintains-buy-on-oncosec-following-fy1q15-update/
$COST William Blair Maintains Outperform On Costco Wholesale Following Fiscal First Quarter Results http://www.smarteranalyst.com/2014/12/11/william-blair-maintains-outperform-on-costco-wholesale-following-fiscal-first-quarter-results/
$CYTX Roth Capital Reiterates Buy On Cytori Therapeutics, Sees 600% Upside http://www.smarteranalyst.com/2014/12/11/roth-capital-reiterates-buy-on-cytori-therapeutics-sees-600-upside/
$GDP Canaccord Reiterates Buy On Goodrich Petroleum Following Capex Budget http://www.smarteranalyst.com/2014/12/11/canaccord-reiterates-buy-on-goodrich-petroleum-following-capex-budget/
$GDP Canaccord Reiterates Buy On Goodrich Petroleum Following Capex Budget http://www.smarteranalyst.com/2014/12/11/canaccord-reiterates-buy-on-goodrich-petroleum-following-capex-budget/
Roth Capital Comments On InvenSense Following Investor Meetings http://www.smarteranalyst.com/2014/12/11/roth-capital-comments-on-invensense-following-investor-meetings/
$SN Canaccord Reiterates Buy On Sanchez Energy Following Financial Update http://www.smarteranalyst.com/2014/12/11/canaccord-reiterates-buy-on-sanchez-energy-following-financial-update/
$TGTX $PCYC Why Wouldn't Pharmacyclics Take TG Out? Roth Capital Comments http://www.smarteranalyst.com/2014/12/11/why-wouldnt-pharmacyclics-take-tg-out-roth-capital-comments/
$CBST Cantor Raises Cubist Pharmaceuticals Price Target In-Line With Merck Offer http://www.smarteranalyst.com/2014/12/11/cantor-raises-cubist-pharmaceuticals-price-target-in-line-with-merck-offer/
$CBST Cantor Raises Cubist Pharmaceuticals Price Target In-Line With Merck Offer http://www.smarteranalyst.com/2014/12/11/cantor-raises-cubist-pharmaceuticals-price-target-in-line-with-merck-offer/
$CYTX Maxim Raises Cytori Price Target As It Gets FDA Conditional Approval For Clinical Trial In Scleroderma http://www.smarteranalyst.com/2014/12/10/maxim-raises-cytori-therapeutics-price-target-as-it-gets-fda-conditional-approval-for-clinical-trial-in-scleroderma/
$CYTX Maxim Raises Cytori Price Target As It Gets FDA Conditional Approval For Clinical Trial In Scleroderma http://www.smarteranalyst.com/2014/12/10/maxim-raises-cytori-therapeutics-price-target-as-it-gets-fda-conditional-approval-for-clinical-trial-in-scleroderma/
Celldex: Merck's Immune Checkpoint Inhibitor Doesn't Threat Glemba, Says Cowen http://www.smarteranalyst.com/2014/12/10/celldex-mercks-immune-checkpoint-inhibitor-doesnt-threat-glemba-says-cowen/
$IDRA Cowen Maintains Outperform On Idera Pharmaceuticals Following Data Releases At ASH http://www.smarteranalyst.com/2014/12/10/cowen-maintains-outperform-on-idera-pharmaceuticals-following-presentations-at/
$IDRA Cowen Maintains Outperform On Idera Pharmaceuticals Following Presentations AT ASH http://www.smarteranalyst.com/2014/12/10/cowen-maintains-outperform-on-idera-pharmaceuticals-following-presentations-at/
$CLNE MLV Cuts Clean Energy Price Target On The Back Of A Steep Decline In Crude Oil Prices http://www.smarteranalyst.com/2014/12/10/mlv-cuts-clean-energy-price-target-on-the-back-of-a-steep-decline-in-crude-oil-prices/
$SNSS Cantor Upgrades Sunesis Pharmaceuticals To Buy Ahead Of FDA Meeting In Early 2015 http://www.smarteranalyst.com/2014/12/10/cantor-upgrades-sunesis-pharmaceuticals-to-buy-ahead-of-fda-meeting-in-early-2015/
$SNSS Cantor Upgrades Sunesis Pharmaceuticals To Buy Ahead Of FDA Meeting In Early 2015 http://www.smarteranalyst.com/2014/12/10/cantor-upgrades-sunesis-pharmaceuticals-to-buy-ahead-of-fda-meeting-in-early-2015/
$TGTX Brean Capital Reiterates Buy On TG Therapeutics Following ASH Presentation http://www.smarteranalyst.com/2014/12/10/brean-capital-reiterates-buy-on-tg-therapeutics-following-ash-presentation/
$TWTR Twitter: Are The Major Events In 4Q Driving MAU Growth? Topeka Says 'No' http://www.smarteranalyst.com/2014/12/10/twitter-are-the-major-events-in-4q-driving-mau-growth-topeka-says-no/
$TWTR Twitter: Are The Major Events In 4Q Driving MAU Growth? Topeka Says 'No' http://www.smarteranalyst.com/2014/12/10/twitter-are-the-major-events-in-4q-driving-mau-growth-topeka-says-no/
$AGIO MLV Reiterates Buy On Agios Pharmaceuticals Following AG-221 Clinical Data Release http://www.smarteranalyst.com/2014/12/10/mlv-reiterates-buy-on-agios-pharmaceuticals-following-ag-221-clinical-data-release/
$AGIO MLV Reiterates Buy On Agios Pharmaceuticals Following AG-221 Clinical Data Release http://www.smarteranalyst.com/2014/12/10/mlv-reiterates-buy-on-agios-pharmaceuticals-following-ag-221-clinical-data-release/
$ANF William Blair Reiterates Outperform On Abercrombie Following The Retirement Of CEO Mike Jeffries http://www.smarteranalyst.com/2014/12/10/william-blair-reiterates-outperform-on-abercrombie-following-the-retirement-of-ceo-mike-jeffries/
$ANF William Blair Reiterates Outperform On Abercrombie Following The Retirement Of CEO Mike Jeffries http://www.smarteranalyst.com/2014/12/10/william-blair-reiterates-outperform-on-abercrombie-following-the-retirement-of-ceo-mike-jeffries/
$AZO Wedbush Reiterates Neutral On AutoZone Following F1Q15 Results http://www.smarteranalyst.com/2014/12/10/wedbush-reiterates-outperform-on-bluebird-bio-following-lentiglobin-data-release/